Company news
Medicus Pharma Ltd. (NASDAQ:MDCX) news
Medicus Pharma Ltd. news releases on 6ix. Latest, Oct 29, 2025: Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue…
Press releases — page 2
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
October 28, 2025
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
October 21, 2025
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
October 13, 2025
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
October 7, 2025
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
September 28, 2025
Medicus Pharma Ltd. To Present at Brookline Capital Markets
September 24, 2025
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
September 17, 2025
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
September 7, 2025
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
September 2, 2025
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights
August 20, 2025
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
August 3, 2025
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
July 22, 2025
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
July 21, 2025
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
July 7, 2025
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
June 29, 2025
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
June 22, 2025
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
June 12, 2025
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
June 8, 2025
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
June 1, 2025
Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
May 30, 2025
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
May 28, 2025
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
May 21, 2025
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
April 27, 2025
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
April 20, 2025
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
March 9, 2025
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
March 5, 2025
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
February 26, 2025
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
February 10, 2025
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
December 11, 2024
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
December 1, 2024
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
November 17, 2024
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
November 14, 2024